Core Points - Genie's Pharma, the largest shareholder of Amgen Pharmaceutical, holds 71.57 million shares, accounting for 10.92% of the total shares [1] - Genie Pharma opposes several proposals at the upcoming extraordinary general meeting, including a plan for Amgen to issue shares to HaiJing Pharmaceutical to raise up to 1.033 billion yuan [1] - If the share issuance is completed, HaiJing Pharmaceutical will hold 20% of Amgen's shares and nominate 5 out of 9 board members, making it the controlling shareholder [1] Proposal Details - The proposal involves Amgen raising funds through a specific share issuance plan, which has raised concerns from Genie Pharma [1] - Genie Pharma's objections include uncertainties regarding the funding from HaiJing Pharmaceutical, potential loss of independence for Amgen, and doubts about the synergy in research and development [1] - Concerns are also raised about HaiJing Pharmaceutical's compliance history and management capabilities, which could impact Amgen's operations [1]

上海盟科药业股份有限公司 2025 年第二次临时股东大会 会议资料 二 O 二五年十月 上海盟科药业股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688373 证券简称：盟科药业 | 2025 年第二次临时股东大会会议议程 5 | | | --- | --- | | 议案一 | 8 | | 关于公司符合向特定对象发行股票条件的议案 | 8 | | 议案二 | 9 | | 关于公司向特定对象发行股票方案的议案 | 9 | | 议案三 | 12 | | 关于公司向特定对象发行股票预案的议案 | 12 | | 议案四 | 13 | | 关于公司向特定对象发行股票方案论证分析报告的议案 | 13 | | 议案五 | 14 | | 关于公司向特定对象发行股票募集资金使用可行性分析报告的议案 14 | | | 议案六 | 15 | | 关于公司引入战略投资者并签署《战略合作协议》的议案 | 15 | | 议案七 | 16 | | 关于签署《附条件生效的向特定对象发行股份认购协议》的议案 16 | | | 议案八 | 17 | | 关于公司向特定对象发行股票涉及关联交易事项的议案 | 17 | | 议案九 ...

证券代码：688373 证券简称：盟科药业 公告编号：2025-052 上海盟科药业股份有限公司 关于2025年第二次临时股东大会增加临时提案暨补 充通知的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 股东大会有关情况 1. 股东大会的类型和届次： 2025年第二次临时股东大会 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | 股 A | 688373 | 盟科药业 | 2025/9/24 | 二、 增加临时提案的情况说明 公司已于2025 年 9 月 23 日公告了股东大会召开通知，单独或者合计持有 10.92%股份的股东Genie Pharma，在2025 年 9 月 24 日提出临时提案并书面提交 股东大会召集人。股东大会召集人按照《上海证券交易所科创板上市公司自律监 2. 股东大会召开日期：2025 年 10 月 9 日 3. 股东大会股权登记日： 1. 提案人：Genie Pharma 2. 提案程序说明 管指引第 1 号 — 规范运 ...

公司及董事会全体成员保证公告内容与 Genie Pharma 提供的信息一致。 证券代码：688373 证券简称：盟科药业 公告编号：2025-051 上海盟科药业股份有限公司 关于股东 Genie Pharma 公开征集投票权的公告 股东 Genie Pharma 保证向公司提供的信息内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 重要内容提示： 按照《中华人民共和国证券法》《上市公司股东会规则》《公开征集上市公 司股东权利管理暂行规定》《上海盟科药业股份有限公司章程》或其他有关规定， 持有上市公司1%以上有表决权股份的股东Genie Pharma作为征集人，就公司拟于 1 征集投票权的起止时间：2025年9月25日至2025年10月6日 Genie Pharma（以下简称"征集人"）对上海盟科药业股份有限公司（以下简 称"公司"或"上市公司"）2025年第二次临时股东大会所审议议案除议案9 外均投反对票； 截至征集公告披露日，征集人Genie Pharma合计持有公司股份数量71,572,817 股，均为有表决权股份，占公司股份总数的10.92%； 征集人 ...

盟科药业(688373.SH)公告称，股东GeniePharma对公司2025年第二次临时股东大会所审议多项议案均投 反对票。GeniePharma合计持有公司股份数量71,572,817股，占公司股份总数的10.92%。征集投票权的 起止时间为2025年9月25日至2025年10月6日。征集人反对原因包括海鲸药业参与定增资金存在不确定 性、销售渠道和人员混同风险、募投项目进度不及预期、利用海鲸药业产能提升盈利能力不确定性以及 研发领域协同效应小等。 ...

Core Viewpoint - The company Mengke Pharmaceutical plans to issue shares to Haiqing Pharmaceutical, which will result in a change of control, with Haiqing holding 20% of the shares and becoming the controlling shareholder [6] Group 1: Share Issuance Details - Mengke Pharmaceutical intends to issue up to 163,901,373 shares at a price of 6.30 yuan per share, raising a total of no more than 1.033 billion yuan, which will be used for daily R&D and operational investments [2][4] - The issuance is aimed at enhancing the company's commercialization capabilities and expanding product sales, as the company currently has limited sales coverage and only one product on the market [4][8] Group 2: Financial Performance - Mengke Pharmaceutical's revenue for 2022, 2023, and 2024 is projected to be 482.07 million yuan, 907.76 million yuan, and 1.30 billion yuan, respectively, with a net profit of -220 million yuan, -421 million yuan, and -441 million yuan [8] - The company has maintained high R&D expenditures, with amounts of 150 million yuan, 345 million yuan, and 369 million yuan for the same years, representing 321%, 379%, and 284% of revenue [8] Group 3: Opposition to the Share Issuance - A board member opposed the share issuance, questioning the fairness, reasonableness, and synergy of the transaction, as well as the clarity of the fundraising plan [5][7] - The board member highlighted the existence of other potential investors with strong collaboration intentions, suggesting that the company did not conduct sufficient investigation and negotiation [7] Group 4: Haiqing Pharmaceutical Overview - Haiqing Pharmaceutical is a research-driven modern pharmaceutical enterprise, focusing on chemical preparations and active pharmaceutical ingredients, with significant market share in the vitamin D2 prescription drug sector [2] - The company has provided over 200 pharmaceutical research or clinical trial services to more than 100 enterprises, including major domestic pharmaceutical companies [2]

Core Viewpoint - The strategic investment by Haiqing Pharmaceutical in Mengke Pharmaceutical marks a significant shift in the latter's ownership structure, with Haiqing becoming the controlling shareholder and aiming to enhance Mengke's capabilities in the antibiotic drug development sector [1][3][4]. Financing and Ownership Changes - Mengke Pharmaceutical plans to raise 1.033 billion yuan through a private placement of 164 million shares at a price of 6.3 yuan per share, which will be used for daily research and operational expenses [3][4]. - Following the issuance, Haiqing Pharmaceutical will hold a 20% stake in Mengke and will nominate five directors to the board, giving it majority control [1][3]. - This marks the first private placement since Mengke's IPO in August 2022, which raised 1.061 billion yuan [3][4]. Financial Performance - From 2021 to mid-2025, Mengke Pharmaceutical generated total revenue of 344 million yuan but incurred a net loss of 1.447 billion yuan, with total R&D expenses amounting to 1.132 billion yuan [6][7]. - The company has not yet achieved profitability, with significant losses reported each year since its product commercialization began in 2021 [6][7]. Strategic Collaboration - A strategic cooperation agreement has been signed between Mengke and Haiqing, focusing on leveraging Mengke's expertise in multi-drug resistant bacteria and Haiqing's established R&D and commercialization capabilities [4][7]. - The collaboration aims to enhance both companies' core competitiveness and facilitate the commercialization of Mengke's products, particularly in the antibiotic sector [4][7]. Market Reaction - Following the announcement of the private placement and strategic partnership, Mengke Pharmaceutical's stock price surged by 20.02%, closing at 9.71 yuan per share [5]. Future Projections - If the collaboration is successful, Mengke aims to achieve sales revenue targets of 260 million yuan, 388 million yuan, and 600 million yuan for the years 2026, 2027, and 2028, respectively [7].

Core Viewpoint - The company plans to raise up to 1.033 billion yuan through a private placement, which will enhance its financial strength and accelerate clinical research and development efforts [4][6]. Group 1: Company Financing and Ownership Changes - The company intends to issue 164 million shares at a price of 6.3 yuan per share to Nanjing Haiqing Pharmaceutical, raising no more than 1.033 billion yuan, which will be used for daily R&D and operational investments [4]. - Following the issuance, Haiqing Pharmaceutical will hold a 20% stake in the company, becoming the controlling shareholder, with Zhang Xiantao as the actual controller [4]. Group 2: Strategic Partnerships and Market Expansion - Haiqing Pharmaceutical, a key player in the chemical pharmaceutical sector, will leverage its extensive sales network and experience to help the company expand its hospital coverage and accelerate commercialization [5]. - The company has set sales revenue targets of 260 million yuan, 388 million yuan, and 600 million yuan for the years 2026 to 2028, respectively [5]. Group 3: Clinical Development Acceleration - The financing will significantly enhance the company's capital strength, expediting the overseas clinical development of antibacterial drugs MRX-5 and MRX-8, which have already completed Phase I trials [6]. - MRX-5 has received FDA orphan drug designation, and successful Phase II trials could substantially increase the company's value [6]. - Surplus funds will also support the advancement of the company's preclinical pipeline, which includes peptide conjugates, antibody-drug conjugates, and other anti-infective drugs [6].

Group 1: Market Overview - The domestic new fund market has seen increased activity, with 63 new funds established this week. Various industry-themed funds exhibited mixed performance, with TMT-themed funds continuing to show a net value increase advantage, while financial and real estate-themed funds experienced notable pullbacks [4]. - Domestic stock ETFs have shifted to net inflows, while Hong Kong stock ETFs continue to see significant inflows. In terms of specific themes, passive funds have reduced holdings in the Sci-Tech Innovation Board and other broad-based ETFs, while financial and real estate-themed ETFs have seen significant net inflows [4]. Group 2: Company Performance - Zhongtie Assembly (300374.SZ) reported a further reduction in losses, with improved cash flow and cash collection ratios year-on-year. For H1 2025, the company achieved total revenue of 870 million yuan, a net loss of 40 million yuan, and a net profit of -40 million yuan, compared to 820 million yuan, -50 million yuan, and -50 million yuan in the same period last year [4]. - Zhongfu Shenying (688295.SH) demonstrated significant improvement in profitability, achieving a turnaround after a year. For H1 2025, the company reported revenue of 920 million yuan, a net profit of 12 million yuan, and a net profit excluding non-recurring items of 2 million yuan, reflecting a year-on-year change of +26%, -52%, and +110% respectively. In Q2 2025, revenue reached 520 million yuan, with a net profit of 60 million yuan and a net profit excluding non-recurring items also at 60 million yuan, showing year-on-year increases of +83%, +440%, and +228% respectively [5]. - Mengke Pharmaceutical (688373.SH) announced a capital increase plan, proposing to issue 164 million shares at a price of 6.3 yuan per share to Nanjing Haiqing Pharmaceutical, raising no more than 1.033 billion yuan. Following the issuance, Haiqing Pharmaceutical will hold a 20% stake in Mengke Pharmaceutical, becoming the controlling shareholder, with individual Zhang Xiantao becoming the actual controller of the company [6].

Core Viewpoint - The announcement of a strategic investment by Nanjing Haiqing Pharmaceutical Co., Ltd. in Mengke Pharmaceutical Co., Ltd. is expected to enhance the latter's cash flow and operational capabilities, despite concerns raised by a board member regarding the fairness and clarity of the transaction [1][3][8]. Group 1: Investment Details - Haiqing Pharmaceutical plans to subscribe for 164 million shares of Mengke Pharmaceutical for no more than 1.033 billion yuan, which will give it a 20% stake and make it the controlling shareholder [1][3]. - The funds raised will be entirely allocated to daily research and operational investments, significantly improving the company's cash flow [1][3][7]. Group 2: Financial Performance - Mengke Pharmaceutical has not yet achieved profitability, with projected revenues of approximately 48 million yuan, 91 million yuan, and 130 million yuan from 2022 to 2024, and net losses of 220 million yuan, 421 million yuan, and 441 million yuan during the same period [6]. - As of mid-2023, the company's cash balance was 269 million yuan, and its debt-to-asset ratio has been increasing, reaching 59.45% [6]. Group 3: Market Reaction - Following the announcement of the investment, Mengke Pharmaceutical's stock price surged, closing at a limit-up price of 9.71 yuan per share, reflecting a 20.02% increase on September 23 [3][4]. - The trading volume reached 1.01 billion yuan, with a turnover rate of 20.43%, indicating strong investor interest [3]. Group 4: Board Member Concerns - Board member Zhao Yachao voted against the investment, citing concerns about the fairness of the transaction, the lack of direct experience of Haiqing Pharmaceutical in the infection field, and the vague fundraising usage plan [8][9]. - Zhao emphasized the need for more thorough investigation and negotiation with other potential investors who have a stronger background in the infection sector [8][9]. Group 5: Future Outlook - Mengke Pharmaceutical aims to leverage the investment to enhance its research and commercialization capabilities, particularly in the field of antibiotic resistance, with sales revenue targets set for 2026-2028 at 260 million yuan, 388 million yuan, and 600 million yuan respectively [7][9].